Find the Perfect Plan for Your Investment Journey
Latest price
52 Week Range
CN¥39.82 - CN¥91.87
Next Earnings Date
May 16 2025 (Estimate)
Next Earnings Date
May 16 2025 (Est.)
Latest price
Market Cap | CN¥40.11B |
EV | CN¥37.08B |
Shares Outstanding | 450.00M |
Beta | 0.55 |
Analyst Rating | BUY |
Analyst Target Price | CN¥75.00 |
P/E 2025E | 24.42x |
P/Revenue 2025E | 9.28x |
Revenue | 88.60% |
EPS | 330.00% |
Operating Cash Flow | 276.70% |
Free Cash Flow | - |
Revenue | 18.10% |
EPS | - |
Operating Cash Flow | - |
Free Cash Flow | - |
Gross Margin 2025E | 95.93% |
Net Profit Margin 2025E | 38.04% |
ROE 2025E | 24.87% |
ROCE 2024 | 32.20% |
DPS 2025E | - |
Payout Ratio 2025E | - |
Div. Yield 2025E | - |
DPS Last 3Y CAGR | - |
Price
%
1M
3M
6M
1Y
3Y
5Y
Shanghai Allist Pharmaceuticals Co., Ltd.
688578
Sector
Healthcare
Industry
Biotechnology
CEO
Du, Jinhao
Employees
1,044
Website
www.allist.com.cnIPO Date
2020-12-02
Headquarters
No. 268 Lingxiaohua Road, Pudong New Area, Shanghai China
COMPANY
NEWSLETTER
© Copyright 2025, All Rights Reserved